Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

This genetic research study uses whole exome sequencing — a test that reads nearly all protein-coding parts of a person's DNA — to search for inherited genetic variants that may explain why some breast cancer patients develop nerve damage (numbness, tingling, or pain in the hands and feet) as a side effect of the chemotherapy drug paclitaxel. **You may be eligible if...** - You are of European American or African American ancestry and have DNA samples available - You are designated as a case (you developed significant nerve damage during paclitaxel treatment) or a control (you completed a full course of paclitaxel without developing nerve damage) **You may NOT be eligible if...** - You do not meet the above ancestry, DNA availability, and case/control designation criteria Talk to your doctor to see if this trial is right for you.